Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a termination agreement with Sorbie Bornholm LP and Sorbie Investments LLP to end a performance-based funding arrangement originally announced on July 29, 2026. The agreement, disclosed in a press release disseminated on behalf of Onco-Innovations Limited, will result in Sorbie returning an aggregate of 5,380,683 common shares for cancellation. This comprises 2,761,635 shares held by Sorbie Bornholm and 2,619,048 shares held by Sorbie Investments.
Under the terms, Sorbie Bornholm will receive the remaining credit support corresponding to C$4,444,444, while Onco-Innovations will relinquish its rights to further payments under the arrangement. Importantly, the transaction will not require any additional cash payment by the company. Additionally, Sorbie Investments will waive its right to receive 2.25 million additional common share purchase warrants, eliminating Onco-Innovations’ obligation to issue those warrants.
The termination remains subject to customary closing conditions, including approval from Cboe Canada, and will take effect on a closing date agreed upon by the parties. For investors, the cancellation of over 5.38 million shares represents a significant reduction in the company’s outstanding share count, which could be accretive to existing shareholders. The elimination of the warrant overhang further simplifies the capital structure and removes potential future dilution. The fact that no additional cash is required preserves the company’s balance sheet as it continues to focus on its oncology research and development efforts.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. The termination of the Sorbie arrangement allows Onco-Innovations to streamline its corporate structure and concentrate resources on advancing its PNKP program.
For full details, the complete press release can be viewed at https://ibn.fm/nx0ZV. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF. This news is important for investors and industry observers because it reflects a strategic decision to clean up the capitalization table and eliminate a funding structure that could have led to further dilution. As a clinical-stage oncology company, Onco-Innovations’ ability to maintain a lean share structure while funding its research is critical to its long-term success. The move may also signal confidence in the company’s alternative funding sources or its overall financial position. The press release was distributed by InvestorWire, a wire service that offers UNLIMITED Words on domestic releases and complimentary Press Release Enhancement. InvestorWire is part of the InvestorBrandNetwork, which includes 50+ brands that provide follow-up coverage. For more information, visit https://www.investorwire.com. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer.
